Pulmonary intravascular coagulation in COVID-19: possible pathogenesis and recommendations on anticoagulant/thrombolytic therapy
- PMID: 32372336
- PMCID: PMC7200048
- DOI: 10.1007/s11239-020-02129-0
Pulmonary intravascular coagulation in COVID-19: possible pathogenesis and recommendations on anticoagulant/thrombolytic therapy
Conflict of interest statement
The authors FBBA and FS declare no conflict of interest.
Figures
Comment on
-
Re: Patiently waiting for the results of anti-IL 6 therapy in severe COVID-19 infection.Autoimmun Rev. 2020 Jul;19(7):102560. doi: 10.1016/j.autrev.2020.102560. Epub 2020 May 1. Autoimmun Rev. 2020. PMID: 32361193 Free PMC article. No abstract available.
References
-
- McGonagle D, O’Donnell JS, Sharif K, Emery P, Bridgewood C. Why the immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia are distinct from macrophage activation syndrome with disseminated Intravascular coagulation. Autoimmun Rev. 2020 doi: 10.1016/j.autrev.2020.102537. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
